St. Luke's University Health Network

Easton, Pennsylvania 18045

3 studies enrolling now · 12 studies all time

What they study most

BRAF Gene Mutation, Covid19, DCIS, Ductal Breast Carcinoma In Situ, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Malignant Melanoma, Melanoma, Metastatic Melanoma, Mismatch Repair-Proficient Colorectal Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer

Studies at this site

• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) — Recruiting now
• The PREDICT Registry: — Recruiting now
• Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma — Recruiting now
• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery — Running, not enrolling
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) — Completed
• Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) — Completed
• COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis — Completed
• A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer — Running, not enrolling
• UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma — Completed
• PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma — Status unconfirmed
• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma — Completed
• A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer — Completed